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MEDICAL GENETICS IN PRACTICE
Letting the family know: balancing ethics and
effectiveness when notifying relatives about genetic
testing for a familial disorder
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Objective: To increase the awareness among at risk relatives of the availability of genetic testing for a
familial disorder while respecting their autonomy and privacy.
Methods: This was a comparison of preintervention and postintervention cohorts of families carried out in
a state wide clinical service providing genetic counselling and testing for people at risk of familial adult
onset cancer. Unaffected relatives who were not clients of the service in 74 kindreds with familial mutations
causing familial breast and ovarian cancer, hereditary non-polyposis colorectal cancer, or Cowden
syndrome were included in the study. In the baseline cohort (41 kindreds), family members who were
clients of the clinical service and had been shown to be carriers of mutations were asked to advise relatives
that genetic testing was available. In the intervention cohort (33 kindreds), the clinical service obtained
consent to advise at risk relatives by letter that genetic testing was available. The main outcome measures
were: (a) proportion of unaffected first and second degree relatives of the proband in each family whose
genetic status was clarified within 2 years of the mutation being identified in the family, and (b) concerns
regarding privacy and autonomy voiced by relatives receiving these letters.
Results: In the baseline cohort, the average proportion of relatives in each family whose genetic status was
clarified was 23%. In the intervention cohort, the average proportion of relatives in each family whose
genetic status was clarified was 40% (p = 0.001). None of the relatives in the intervention cohort
complained of a breach of privacy or autonomy.
Conclusion: Clinical services can take an effective and proactive approach to notifying relatives who are
not their clients of the availability of genetic testing without compromising principles of privacy and
autonomy.
G
enetic testing is increasingly being used in the
management of familial disorders. Identifying the
causative mutation may not alter the medical care
offered to the patient, but it does allow the genetic status of
unaffected at risk relatives to be clarified. These relatives may
seek presymptomatic genetic testing as a prelude to making
significant reproductive or medical decisions, or to facilitate
such decision making by their children. Those identified as
carriers can undertake strategies to reduce their risk of
disease or facilitate early diagnosis, and non-carriers can
avoid the costs of unnecessary interventions. Both outcomes
yield benefits to individuals and society.
The uptake of presymptomatic genetic testing among
relatives varies greatly and is influenced by a variety of
social, genetic, and psychological factors.1–5 For the patient
identified with the mutation, the process of advising relatives
that genetic testing is available is by no means simple.6–13
There has also been extensive debate about the need to
respect the privacy of those undergoing genetic testing, the
rights of their relatives to be notified of significant genetic
information, and the extent to which families or service
providers should be responsible for notifying them.14–23
Conversely, relatives may regard the unsolicited provision of
information about a familial disorder as an invasion of their
own privacy, with the potential for adverse psychological and
financial (for example, insurance) consequences. There is
also the possibility that at risk relatives could feel pressured
by family members to pursue presymptomatic genetic testing.
The challenge for those providing clinical programmes is to
devise a process for advising relatives that addresses these
diverse and competing requirements. With the advent of
genetic testing for common familial disorders such as familial
cancer, familial hypercholesterolaemia, and hereditary cardio-
myopathies, there is a need to develop efficient, effective,
and acceptable procedures for informing relatives.
The South Australian Familial Cancer Service (FCS)
provides genetic services for patients with familial cancer
and their families. We initially left the dissemination of
genetic information to relatives in the hands of the family
members who were already clients of our service, but the low
uptake of presymptomatic genetic testing among these
relatives suggested that information about the availability
of genetic counselling and testing was not being effectively
shared within families. We have trialled a process for
informing relatives that meets the competing requirements
of disseminating information with significant medical and
social consequences while respecting principles of privacy




The FCS was established in 1998 as the sole provider of
genetic education, counselling, and testing for familial cancer
in the State. These services are provided at no direct cost to
clients. The FCS does not provide cancer surveillance,
diagnostic, or therapeutic services, but liaises closely with
other established service providers.
Abbreviation: FCS, Familial Cancer Service
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The kindreds selected for this study had autosomal
dominant mutations responsible for adult onset familial
cancer syndromes: familial breast/ovarian cancer (BRCA1 and
BRCA2 genes; 56 kindreds), hereditary non-polyposis color-
ectal cancer (MLH1, MSH2, and MSH6 genes; 17 kindreds),
and Cowden syndrome (PTEN gene; one kindred). There was
a minimum of 2 years’ follow up after each kindred’s
mutation had been identified, and all follow up was censored
at 31 December 2004. The analysis was initially restricted to
eligible unaffected first and second degree relatives (hereafter
described as close relatives) of the first person in the family
identified with the mutation (the proband). These relatives
were at 25–50% risk of being carriers of the mutation. To be
eligible for presymptomatic testing through the FCS, a close
relative had to reside in South Australia, not have had a
diagnosis of cancer, and be aged 16 years or older.
Probands had genetic testing initiated by the clinic on the
basis of the reported family history; relatives were not
necessarily contacted by the FCS as a prelude to such testing.
Approximately 85% of the kindreds were also involved in
research studies. These studies did not involve the provision
of genetic information or advice to subjects, and the baseline
and intervention cohorts (described below) had the same
proportions of research kindreds. Hence the impact of the
intervention could be assessed independently of the effect of
involvement in research.
Intervention strategy
Prior to 2001, probands with a heritable mutation were
advised that close relatives were at high risk of having the
same mutation. It was recommended both at the appoint-
ment and in a subsequent telephone call and letter that the
proband should advise close relatives to seek further
information from their doctor or the FCS. The baseline
cohort of families was drawn from this experience.
From 2001, the Service began writing directly to the close
relatives of documented carriers in newly identified kindreds
to advise them of the cancer risk and availability of genetic
counselling and testing. These kindreds constituted the
intervention cohort. This process was not designed to replace
the sharing of information among relatives by word of
mouth, but was established as a supplementary process. The
following process was approved by the institutional ethics
committee:
1. As part of pretest counselling, the proband was
requested to acknowledge the role of the Service in
advising relatives. The wording in the consent form was,
‘‘I understand that the diagnosis of familial cancer may
have implications for other members of my family and
that I may be asked to assist the Familial Cancer Service
in informing them’’. Acceptance of this request was
encouraged but was not mandatory.
2. Once a mutation had been identified, the proband
provided contact details for adult close relatives residing
in South Australia or elsewhere in Australia. Contact
details were not sourced or validated from other sources
(thereby ensuring that the proband controlled the
process).
3. The FCS sent a letter to each close relative. The timing of
this letter was decided with the proband to allow for
informal contact with relatives. Some probands were
keen to contact their relatives informally, others agreed
with reluctance, while others declined to do so and were
relieved that the unit would notify their families.
4. The wording of the letter was in general terms and did
not identify the proband (thereby protecting the
proband’s privacy) or the familial cancer syndrome,
mutation, or details of cancer risk (thereby reducing the
potential for adverse impact on the recipient’s insur-
ability in Australia). The text of the letter and response
sheet are shown in the appendix (figs A and B).
5. If the proband was unwilling to provide contact details
but agreed to contact the relative, the letter was given to
the proband to pass to the relative.
6. South Australian relatives who sought further informa-
tion were offered an appointment; interstate relatives
were directed to their local services. The proband was
not advised which relatives responded to the letter
(thereby protecting the privacy of relatives).
7. If presymptomatic genetic testing identified another
carrier, the carrier was asked to provide contact details
for other close relatives (as in step 2 above), and the
cycle was repeated. The further medical management of
the carrier was arranged through their general practi-
tioner and local specialist services.
8. The FCS did not seek further contact with relatives who
did not respond to the letter, even if another carrier
subsequently provided the relative’s contact details
(thereby avoiding the risk of harassing those who did
not want information).
This intervention only applied to relatives who were not
already clients of the FCS. Relatives who had already
attended appointments prior to a mutation being identified
were advised by letter of the mutation, the associated cancer
risks, and that genetic testing was available.
For data management, we used a hybrid system consisting
of the Progeny database (www.progeny2000.com) and the
KinTrak client interface (www.kintrak.com). This combina-
tion allowed for simultaneous graphical review of a pedigree
and efficient manipulation of textual data.
Outcome measures
The FCS encouraged clients to make informed choices
regarding genetic testing and cancer surveillance. Relatives
who made an informed choice not to have testing could have
represented as successful an outcome as those who proceeded
with testing, but it was impossible to quantify the degree to
which this goal was achieved. For this reason, the number of
close relatives whose genetic status was defined was used as
a surrogate measure of outcome. Genetic status was
determined either by genetic testing or by a parent being
shown to be a non-carrier (thereby precluding their children
from inheriting the mutation from this parent, and making
the children presumed non-carriers); none of the presumed
non-carriers subsequently sought genetic testing to confirm
the inferred genetic status.
The x2 test or two tailed t test was used to assess the
significance of differences between the two cohorts.
RESULTS
Effect of letters versus no letters within first 2 years
The characteristics of the two cohorts and the outcome of
genetic testing within the first 2 years of a mutation being
identified in the proband are summarised in table 1. The
response in different families varied markedly. In both
cohorts, there were families in which no presymptomatic
genetic testing of close relatives was performed within the
first 2 years, and others in which all eligible close relatives
had their genetic status defined promptly. On average, 23% of
close relatives in families in the baseline cohort had their
genetic status defined within 2 years compared with 40% in
families from the intervention cohort (p = 0.001).
Of the 442 close relatives in the intervention cohort,
contact details were provided for 140 who were then sent a
letter by the FCS. A further 39 letters were provided via
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probands. In families in which one or more letters were
provided via the proband, an average of 24% of eligible close
relatives in the family had their genetic status clarified within
2 years of the mutation being identified. In contrast, in
families in which all the letters were sent by the Service, an
average of 46% of eligible close relatives in the family had
their genetic status clarified within 2 years (p = 0.03). Of the
88 relatives in this cohort who sought testing within 2 years,
40 had been posted a letter by the FCS and only two had been
provided with a letter via the proband (p = 0.01); the
remaining 46 relatives who sought testing had not been sent
letters because they were already clients of the FCS by the
time letters were due to be sent out. The lack of response to
letters provided via the proband could reflect the relatives’
lack of interest or a failure by the proband to deliver the
letter; this issue was not explored.
Approximately 12% of the relatives in the intervention
cohort whose contact details were provided lived outside
South Australia and hence their response to the offer of
genetic counselling was not necessarily known. If the
relatives living outside South Australia had responded to
the same degree as those within the state, the overall
response rates would have been 14% higher than shown.
Overall effect of all letters sent to relatives
Letters were subsequently provided for the probands’ close
relatives in the baseline cohort. This occurred after 2001 and
was more than 2 years after mutations had been identified in
these kindreds. Letters were also provided for the close
relatives of other carriers in both cohorts—that is, for more
distant relatives of probands who were at 25–50% risk of
having the mutation. In the period 2001–2003, the FCS sent
140 letters to close relatives in the intervention cohort (as
described above) and an additional 211 letters to other
relatives living in South Australia. The FCS also provided 39
letters for probands to pass on to close relatives in the
intervention cohort (as described above); an additional 201
letters were provided to pass on to other relatives.
Of the 591 relatives receiving letters by post or via the
proband, 19% sought presymptomatic genetic testing, a
further 8% were identified as presumed non-carriers, and
7% sought further information from the FCS but did not
proceed to have genetic testing. Hence, a total of 34% of
recipients (responders) either had their genetic status defined
or sought further information about the availability of
genetic testing. The remaining 66% (non-responders) had
not responded by the end of the follow up period (December
2004).
Among all the relatives seeking presymptomatic testing,
there was no significant difference in relation to age, gender,
or gene involved (BRCA1/2 compared with other genes),
between those who had been sent a risk notification letter by
the FCS and those who had not (data not shown). In each of
the first 3 years after the introduction of the letters, similar
proportions of recipients responded within 12 months of a
letter being sent (31%, 25%, and 25% during 2001, 2002, and
2003 respectively; p = 0.4, x2 test).
When the South Australian relatives who had been sent a
letter by the FCS were partitioned into responders and non-
responders, there was no association between response and
several parameters (table 2). Relatives who were shown to be
presumed non-carriers (n = 13) were excluded from this
analysis; those who advised us that they did not want
information (n = 25) were counted as non-responders. The
duration of follow up ranged from 12 to 60 months.
Adverse responses to letters
Of the 351 relatives sent a letter by the FCS, 25 (7%)
contacted us to indicate that they did not want further
information about familial cancer risk. None complained of a
breach of privacy or sought to have identifying information
removed from the unit’s database, and no complaints were
received by our host institution.
DISCUSSION
Significance and effectiveness of notifying relatives
The most important clinical benefit arising from the
identification of a mutation may be the ability to define the
status of at risk relatives who have yet to attend the clinic.
Once we began to notify relatives who were not clients of our
FCS that genetic testing was available, the proportion of close
relatives in each family whose genetic status was clarified
within 2 years almost doubled.
There are a number of aspects of this investigation that
merit further attention. We did not explore the dynamic
between person to person communication about risk and the
more formal (and less specific) letter from the FCS, 11 nor did
we try to determine why non-responders elected not to seek
further information regarding such a significant health issue.
We found that, irrespective of the delay between the
kindred’s mutation being identified and letters being sent
to relatives, the proportion of recipients seeking further
information was no higher than 34%. We do not know what
factors set this limit, but recognise that issues of confidenti-
ality, fear of cancer, or a perception that surveillance is
ineffective may have been involved.
Table 1 Outcome in baseline (B) and intervention (I)
cohorts in first 2 years
Parameter B I p value
No. of probands 41 33
Total no. of probands’ close relatives
(all states)
411 442
Average age of probands (years) 52.3 52.0 0.9
No. of female probands 37 31 0.6
No. of breast cancer kindreds 31 25 1.0
No. of close relatives per proband 10.0 13.4 0.07
No. of close relatives tested in SA 62 88
No. of close relatives shown to be
presumed non-carriers in SA
27 59
Total no. of close relatives with carrier
status defined in SA
89 147
Average proportion of close relatives in











No. of relatives 134 204
Average age of recipients
(if known) (years)
46 47 0.5
No. (%) in research
kindreds
120 (90%) 182 (89%) 0.9
No. (%) who were close
relatives of proband
67 (50%) 110 (54%) 0.5
No. (%) sent letter more
than 2 years after
mutation was identified
53 (40%) 88 (43%) 0.5
No. (%) in BRCA kindreds 104 (78%) 164 (80%) 0.5
No. (%) of male recipients 67 (50%) 120 (59%) 0.1
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It is clear that providing letters to relatives via the proband
is not as effective as sending letters directly to the relatives.
This could reflect the reticence of probands to pass these
letters on, or that the proband’s inability (or unwillingness)
to provide contact details for these relatives reflects a degree
of emotional distance from the relative.8 A proactive approach
by the counsellor can increase the proportion of close
relatives to whom the letter is sent by the FCS; in the period
2001–2004, the proportion of relatives sent letters by the FCS
(rather than via the proband) increased steadily by 16% (data
not shown).
This study was intrinsically weakened by the use of a
historical cohort to provide baseline measures of outcome.
The past decade has been a period of increasing public
awareness of genetics in healthcare, and this may have
resulted in a change in the types of patients seeking genetic
counselling and testing, but there were no significant
differences in age, sex, or the gene involved in the probands
from the two cohorts or among those seeking presympto-
matic testing. In each of the first 3 years in which we sent
letters to relatives, the response rates were stable and did not
suggest that there was a growing interest in genetic testing.
These observations do not suggest that there was a systematic
change in patient type or attitudes over this period.
Ethical issues in notifying relatives
There are a host of ethical issues that can complicate the
process of a clinical service contacting relatives who are not
clients of that service.10 18 20 21 23 The provision of a formal
communication to relatives by a service provider has the
advantage of reducing the burden on the proband to advise
relatives about a medically and ethically complex issue while
providing the relatives with greater autonomy in deciding
what to do with this information. If this information is
provided exclusively by the proband, relatives may feel
pressured by the proband’s expectations to undertake testing.
After all, the proband has already demonstrated an interest in
genetic testing that may not be shared by their relatives. The
provision of this information by a disinterested service
provider gives the family members the opportunity to make
some separation between their emotional and genetic
relationships.
The strategy outlined in this study provides information to
relatives in a staged fashion. In the first step, the formal
communication simply advises relatives in very general terms
that medically significant information is available. The lack of
specific detail provides the family members with another
opportunity to separate their emotional and genetic relation-
ships, as it is not assumed that relatives will want to know
the implications of diagnoses in other family members.
Relatives can readily obtain more detailed information
without involving the proband, thereby avoiding the pro-
band’s expectation that they will have a presymptomatic
genetic test.
The letter sent to relatives requested that those seeking an
appointment with the FCS obtain a referral from their
general practitioner. While the FCS has a policy of accepting
self referrals for genetic counselling and testing, we prefer to
have general practitioner involvement from the outset. Of the
recipients who sought an appointment, 47% did not provide a
referral. This reflected the convenience of making a prompt
appointment with the FCS rather than concerns about
confidentiality. During the appointment, those without
referrals were asked for permission to provide their doctors
with the outcome of presymptomatic testing, and with rare
exceptions, this was provided. We have no evidence that
concern regarding doctors’ access to confidential information
was a significant factor in recipients deciding whether to
pursue the offer of genetic counselling and testing.
This formal communication could be delivered by the
proband or posted directly to the relatives, and there are some
ethical distinctions between the two approaches (table 3).
Although local attitudes and legislation may determine
which method is more ethically appropriate in a specific
situation, posting letters directly to at risk relatives seemed to
be more effective. The fact that a recipient of such a letter
must initiate a request for further information and that the
service provider does not follow up non-responders gives the
Table 3 Comparison of ethical issues in sending letters to relatives via proband or by post
Issue
Ethical consideration
Letter provided via proband Letter posted by FCS
The proband’s decision to have genetic testing
should not be conditional on consent to notify
relatives.
The proband could choose whether to notify relatives.
The proband’s decision to have genetic testing
should not be conditional on involvement in
notifying relatives.
The proband could choose whether to deliver
letters to relatives.
Involvement of the Unit reduced the demand placed
on the proband to notify relatives.
The right of the carrier of a mutation to maintain
privacy should be upheld.
The proband could choose to post letters
anonymously.
The letter sent by the Unit did not identify the proband.
At-risk relatives should be advised of genetic
risks that may have significant personal
consequences for them.
Lower response rate suggests that some
probands may have failed to pass letter on,
thereby denying relatives the opportunity to
respond.
Higher response rate suggests that more relatives
were given the opportunity to respond.
The privacy of at-risk relatives should be upheld. Contact details of relatives were not provided
by the proband. The Unit did not advise the
proband if relatives sought genetic testing.
Contact details of relatives were only obtained from
the proband. The Unit did not advise the proband of
the responses of relatives.
At-risk relatives should be able to decide how
much genetic information they wish to access.
At-risk relatives chose whether to access further information and whether to involve their doctor.
The notification of genetic risk should not
compromise financial decisions that at-risk
relatives may make.
The general information provided in the letter did not specify the disorder in the family or the degree of risk.
The interest of multiple relatives in genetic testing
should not take precedence over an individual’s
autonomy.
A relative could be provided with multiple
letters by other family members who had
sought genetic testing.
Relatives who did not seek further information were
not approached by the FCS again, even if other
relatives provided their contact details.
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relative control over the process of obtaining and using this
information.
The provision of de-identified information by a clinical
service does not necessarily provide anonymity for all family
members. Informal communication between family members
will frequently have identified the proband prior to receipt of
the letter from the service. However, the provision of de-
identified information without the proband necessarily being
involved, as well as the confidentiality of the recipient’s
response to the clinical service, ensures that anonymity is not
compromised by the notification process.
Only two probands refused permission for the FCS to
notify relatives. One proband had been in the baseline cohort
in which consent for sending letters had not been sought
prior to testing; when she was subsequently approached for
consent to contact to her relatives, she declined. More
recently, a proband who was not part of this study refused
permission. There are a couple of factors which may account
for the low incidence of this response in South Australia in
contrast to other centres.17 The FCS does not offer cancer
diagnostic or therapeutic services, thereby making it clear
that ‘‘the family’’ is the unit of care rather than one person.
We also introduce the concept of the ‘‘family covenant’’24
early in the process of our consultation with the proband,
highlighting that testing for a heritable mutation defines an
attribute of the family rather than just an individual, and that
the main beneficiaries of the test are likely to be unaffected
family members who have yet to attend the clinic.
None of the recipients of letters from the FCS complained
of a breach of their privacy. This may be due to the careful
wording of our letter, or it may simply reflect local views
about privacy and the role of healthcare providers in South
Australia. In our letter, we did not seek to elicit negative
responses from recipients and, despite 7% of recipients
advising us that they did not want further information, none
complained of such a breach. During the period of this study,
three of the 2090 clients referred by doctors to our FCS
requested that identifying information be removed from our
database, indicating that South Australians are not unaware
of their right to privacy. We have also sought publicity for our
programme, we have the support of local cancer specialists,
and we have highlighted the involvement of a respected
philanthropic organisation in funding the programme. We
did not examine the degree to which these various factors
may have contributed to the lack of adverse responses, and
recognise that our strategy might elicit such responses in
other settings.
Managing the process of notifying relatives
Managing the notification, counselling, testing, and subse-
quent follow up of relatives in an extended family requires a
family based data management system. Such a system does
not replace the need for expert genetic counselling, but it is
necessary for reasons of efficiency (reducing the numbers of
staff required) and effectiveness (recognising the medico-
legal implications of advising relatives). In 2004, we provided
genetic counselling for 800 clients and sent 700 risk advice
letters to relatives with the equivalent of only 4.4 clinical
staff. Careful record keeping is also essential because of the
potential delay between a relative being advised of the
availability of genetic testing and the relative seeking such a
test. Although the majority of those seeking genetic counsel-
ling and testing did so within 18 months of receiving a letter,
there were continuing requests for information 4 years later.
CONCLUSION
A programme of genetic testing for a familial disorder must
reach beyond the affected patient and address the potential
needs of at risk relatives. Clinical services can provide useful
information to relatives who are not their clients without
compromising principles of privacy and autonomy. The
complexities of managing genetic testing in families demand
careful planning, expert genetic counselling, and sophisti-
cated data management. However, the service’s proactive
approach to notifying relatives results in a much greater
proportion of at-risk relatives making informed decisions
about genetic testing for the family’s disorder.
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PLEASE RETURN THIS FORM IN THE REPLY PAID ENVELOPE
Your name:





Please indicate your decision (tick one box), sign the form, and send
it back to us in the reply-paid envelope.
     I want an appointment with a genetic counsellor.
We recommend that you get a referral letter from your doctor for
this appointment.
We will write to you doctor after your appointment.
     I do not want an appointment. Please contact my doctor.
My doctor's name is
My doctor's address or suburb is
My doctor's telephone number is
If you do not want further information or an appointment at this 
stage, you are free to change your mind in the future.
The information provided will be kept in our files and it may be recorded in the database 
of the SA Clinical Genetics Service. Please keep us informed of any changes to this 
information. The information is used by staff of the service for various functions both now 
and in the future including clinical care of individuals and their families, administration, 
auditing clinical & laboratory activities, and research. The database operates in
accordance with the SA Department of Health's Code of Fair Information Practice.
Figure B Response sheet included with letter provided by the Familial
Cancer Service.
APPENDIX
Dear                 ,
The Familial Cancer Unit is part of the South Australian Familial
Cancer Service. I am writing to you at the request of one of your 
relatives because they wish to share important health information
with you.
A member of your family has been found to have an inherited
tendency to develop cancer. This may mean that there is an 
increased chance of you developing cancer. Even if people have
not developed cancer themselves, they can pass this inherited
tendency to their children. If a person has an increased chance
of developing cancer, there are effective ways of reducing this risk.
What can you do now?
We recommend that you discuss this letter with your doctor. We
can provide your doctor with further information about the family's 
situation as well as assistance in managing your cancer risk.
We also recommend that you discuss this matter with a counsellor
at a genetics clinic.
A genetic counsellor can offer you:
Assessment about your chance of having this condition or of
developing cancer.
Advice to you and your doctor about managing your chance of
developing cancer.
Genetic testing is now available if you want to know whether
you have inherited the family's tendency to develop cancer or not. 
There is no obligation for you to have a test.
Research studies about inherited cancer are available for some 
families.
Please let us know if you would like to find out more about the
services available to you by indicating your response on the
enclosed form and sending it back to us. These services are 
available at no cost to you. Please be assured that the information
we give you and any information we receive from you is treated 
confidentially.
We urge you to take this matter seriously as this 
information can be life saving.
Please do not hesitate to call the Unit if you have any concerns or
questions.
Yours sincerely,
Head, Familial Cancer Clinic
Figure A Text of letter provided by the Familial Cancer Unit to close
relatives of the proband or other carriers. The letter was either sent by
mail directly to the relative or sent via the proband.
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